Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-γ production, and expansion of natural killer cells
We investigated the in vitro effects of combining interleukin-18 (IL-18) and IL-2 on human lymphocytes. The combined use of these two cytokines synergistically enhanced the proliferation, cytolytic activity, and interferon-gamma production of peripheral blood mononuclear cells. Phenotypic analysis r...
Gespeichert in:
| Veröffentlicht in: | Cancer research (Chicago, Ill.) Ill.), 2001-02, Vol.61 (3), p.884-888 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 888 |
|---|---|
| container_issue | 3 |
| container_start_page | 884 |
| container_title | Cancer research (Chicago, Ill.) |
| container_volume | 61 |
| creator | SON, Young-Ik DALLAL, Ramsey M MAILLIARD, Robbie B EGAWA, Shinichi JONAK, Zdenka L LOTZE, Michael T |
| description | We investigated the in vitro effects of combining interleukin-18 (IL-18) and IL-2 on human lymphocytes. The combined use of these two cytokines synergistically enhanced the proliferation, cytolytic activity, and interferon-gamma production of peripheral blood mononuclear cells. Phenotypic analysis revealed a preferential expansion of CD56+CD3- cells and an up-regulation of IL-2 receptor-alpha expression on natural killer cells. Isolated natural killer cells showed a substantial increase in proliferation and cytotoxicity compared with CD4+ and CD8+ T cells. The combined use of IL-18 and IL-2 should be considered a viable strategy to induce an antitumor response in vivo. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_11221875</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11221875</sourcerecordid><originalsourceid>FETCH-LOGICAL-p235t-3787befdf036c19bc485840a06fcde40556b14dff25093d9bee26378a3de36f73</originalsourceid><addsrcrecordid>eNo9kN9KwzAYxYMobk5fQQLeKKyQNE2bXsrwz2DgjV6PNPni4rK0JClar30j38NnsuL06nAOv-_A-Q7QlHImsqoo-CGaEkJExosqn6CTGF9Gyynhx2hCaZ5TUfEp-lj6BMFBv7U-owJfLlejXOE4eAjP9h0ifrVpg8c4x6nF4DfSK8BqSG1q36yyaZhj-1NiILQ--_rEXWh1r5Jt_RxLrzG8ddLH0eLWYC9TH6TDW-scBKzAuXiKjox0Ec72OkNPtzePi_ts9XC3XFyvsi5nPGWsElUDRhvCSkXrRhWCi4JIUhqloSCclw0ttDE5JzXTdQOQl-ORZBpYaSo2Q-e_vV3f7ECvu2B3Mgzrv3eMwMUekFFJZ8K41cZ_TtQlJ4x9A9jqayQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-γ production, and expansion of natural killer cells</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>SON, Young-Ik ; DALLAL, Ramsey M ; MAILLIARD, Robbie B ; EGAWA, Shinichi ; JONAK, Zdenka L ; LOTZE, Michael T</creator><creatorcontrib>SON, Young-Ik ; DALLAL, Ramsey M ; MAILLIARD, Robbie B ; EGAWA, Shinichi ; JONAK, Zdenka L ; LOTZE, Michael T</creatorcontrib><description>We investigated the in vitro effects of combining interleukin-18 (IL-18) and IL-2 on human lymphocytes. The combined use of these two cytokines synergistically enhanced the proliferation, cytolytic activity, and interferon-gamma production of peripheral blood mononuclear cells. Phenotypic analysis revealed a preferential expansion of CD56+CD3- cells and an up-regulation of IL-2 receptor-alpha expression on natural killer cells. Isolated natural killer cells showed a substantial increase in proliferation and cytotoxicity compared with CD4+ and CD8+ T cells. The combined use of IL-18 and IL-2 should be considered a viable strategy to induce an antitumor response in vivo.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 11221875</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; CD4-Positive T-Lymphocytes - drug effects ; CD4-Positive T-Lymphocytes - immunology ; CD4-Positive T-Lymphocytes - metabolism ; CD8-Positive T-Lymphocytes - drug effects ; CD8-Positive T-Lymphocytes - immunology ; CD8-Positive T-Lymphocytes - metabolism ; Cell Division - drug effects ; Cytotoxicity, Immunologic - drug effects ; Drug Synergism ; Humans ; Immunotherapy ; Interferon-gamma - biosynthesis ; Interleukin-18 - pharmacology ; Interleukin-2 - pharmacology ; Killer Cells, Natural - drug effects ; Killer Cells, Natural - immunology ; Killer Cells, Natural - metabolism ; Leukocytes, Mononuclear - drug effects ; Leukocytes, Mononuclear - immunology ; Leukocytes, Mononuclear - metabolism ; Lymphocyte Activation - drug effects ; Lymphocytes - drug effects ; Lymphocytes - immunology ; Lymphocytes - metabolism ; Lymphoma, B-Cell - immunology ; Medical sciences ; Pharmacology. Drug treatments ; Receptors, Interleukin-2 - biosynthesis ; Tumor Cells, Cultured ; Up-Regulation - drug effects</subject><ispartof>Cancer research (Chicago, Ill.), 2001-02, Vol.61 (3), p.884-888</ispartof><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=896503$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11221875$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SON, Young-Ik</creatorcontrib><creatorcontrib>DALLAL, Ramsey M</creatorcontrib><creatorcontrib>MAILLIARD, Robbie B</creatorcontrib><creatorcontrib>EGAWA, Shinichi</creatorcontrib><creatorcontrib>JONAK, Zdenka L</creatorcontrib><creatorcontrib>LOTZE, Michael T</creatorcontrib><title>Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-γ production, and expansion of natural killer cells</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>We investigated the in vitro effects of combining interleukin-18 (IL-18) and IL-2 on human lymphocytes. The combined use of these two cytokines synergistically enhanced the proliferation, cytolytic activity, and interferon-gamma production of peripheral blood mononuclear cells. Phenotypic analysis revealed a preferential expansion of CD56+CD3- cells and an up-regulation of IL-2 receptor-alpha expression on natural killer cells. Isolated natural killer cells showed a substantial increase in proliferation and cytotoxicity compared with CD4+ and CD8+ T cells. The combined use of IL-18 and IL-2 should be considered a viable strategy to induce an antitumor response in vivo.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>CD4-Positive T-Lymphocytes - drug effects</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD4-Positive T-Lymphocytes - metabolism</subject><subject>CD8-Positive T-Lymphocytes - drug effects</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>CD8-Positive T-Lymphocytes - metabolism</subject><subject>Cell Division - drug effects</subject><subject>Cytotoxicity, Immunologic - drug effects</subject><subject>Drug Synergism</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Interferon-gamma - biosynthesis</subject><subject>Interleukin-18 - pharmacology</subject><subject>Interleukin-2 - pharmacology</subject><subject>Killer Cells, Natural - drug effects</subject><subject>Killer Cells, Natural - immunology</subject><subject>Killer Cells, Natural - metabolism</subject><subject>Leukocytes, Mononuclear - drug effects</subject><subject>Leukocytes, Mononuclear - immunology</subject><subject>Leukocytes, Mononuclear - metabolism</subject><subject>Lymphocyte Activation - drug effects</subject><subject>Lymphocytes - drug effects</subject><subject>Lymphocytes - immunology</subject><subject>Lymphocytes - metabolism</subject><subject>Lymphoma, B-Cell - immunology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Interleukin-2 - biosynthesis</subject><subject>Tumor Cells, Cultured</subject><subject>Up-Regulation - drug effects</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kN9KwzAYxYMobk5fQQLeKKyQNE2bXsrwz2DgjV6PNPni4rK0JClar30j38NnsuL06nAOv-_A-Q7QlHImsqoo-CGaEkJExosqn6CTGF9Gyynhx2hCaZ5TUfEp-lj6BMFBv7U-owJfLlejXOE4eAjP9h0ifrVpg8c4x6nF4DfSK8BqSG1q36yyaZhj-1NiILQ--_rEXWh1r5Jt_RxLrzG8ddLH0eLWYC9TH6TDW-scBKzAuXiKjox0Ec72OkNPtzePi_ts9XC3XFyvsi5nPGWsElUDRhvCSkXrRhWCi4JIUhqloSCclw0ttDE5JzXTdQOQl-ORZBpYaSo2Q-e_vV3f7ECvu2B3Mgzrv3eMwMUekFFJZ8K41cZ_TtQlJ4x9A9jqayQ</recordid><startdate>20010201</startdate><enddate>20010201</enddate><creator>SON, Young-Ik</creator><creator>DALLAL, Ramsey M</creator><creator>MAILLIARD, Robbie B</creator><creator>EGAWA, Shinichi</creator><creator>JONAK, Zdenka L</creator><creator>LOTZE, Michael T</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20010201</creationdate><title>Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-γ production, and expansion of natural killer cells</title><author>SON, Young-Ik ; DALLAL, Ramsey M ; MAILLIARD, Robbie B ; EGAWA, Shinichi ; JONAK, Zdenka L ; LOTZE, Michael T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p235t-3787befdf036c19bc485840a06fcde40556b14dff25093d9bee26378a3de36f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>CD4-Positive T-Lymphocytes - drug effects</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD4-Positive T-Lymphocytes - metabolism</topic><topic>CD8-Positive T-Lymphocytes - drug effects</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>CD8-Positive T-Lymphocytes - metabolism</topic><topic>Cell Division - drug effects</topic><topic>Cytotoxicity, Immunologic - drug effects</topic><topic>Drug Synergism</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Interferon-gamma - biosynthesis</topic><topic>Interleukin-18 - pharmacology</topic><topic>Interleukin-2 - pharmacology</topic><topic>Killer Cells, Natural - drug effects</topic><topic>Killer Cells, Natural - immunology</topic><topic>Killer Cells, Natural - metabolism</topic><topic>Leukocytes, Mononuclear - drug effects</topic><topic>Leukocytes, Mononuclear - immunology</topic><topic>Leukocytes, Mononuclear - metabolism</topic><topic>Lymphocyte Activation - drug effects</topic><topic>Lymphocytes - drug effects</topic><topic>Lymphocytes - immunology</topic><topic>Lymphocytes - metabolism</topic><topic>Lymphoma, B-Cell - immunology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Interleukin-2 - biosynthesis</topic><topic>Tumor Cells, Cultured</topic><topic>Up-Regulation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SON, Young-Ik</creatorcontrib><creatorcontrib>DALLAL, Ramsey M</creatorcontrib><creatorcontrib>MAILLIARD, Robbie B</creatorcontrib><creatorcontrib>EGAWA, Shinichi</creatorcontrib><creatorcontrib>JONAK, Zdenka L</creatorcontrib><creatorcontrib>LOTZE, Michael T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SON, Young-Ik</au><au>DALLAL, Ramsey M</au><au>MAILLIARD, Robbie B</au><au>EGAWA, Shinichi</au><au>JONAK, Zdenka L</au><au>LOTZE, Michael T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-γ production, and expansion of natural killer cells</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>2001-02-01</date><risdate>2001</risdate><volume>61</volume><issue>3</issue><spage>884</spage><epage>888</epage><pages>884-888</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>We investigated the in vitro effects of combining interleukin-18 (IL-18) and IL-2 on human lymphocytes. The combined use of these two cytokines synergistically enhanced the proliferation, cytolytic activity, and interferon-gamma production of peripheral blood mononuclear cells. Phenotypic analysis revealed a preferential expansion of CD56+CD3- cells and an up-regulation of IL-2 receptor-alpha expression on natural killer cells. Isolated natural killer cells showed a substantial increase in proliferation and cytotoxicity compared with CD4+ and CD8+ T cells. The combined use of IL-18 and IL-2 should be considered a viable strategy to induce an antitumor response in vivo.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>11221875</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-5472 |
| ispartof | Cancer research (Chicago, Ill.), 2001-02, Vol.61 (3), p.884-888 |
| issn | 0008-5472 1538-7445 |
| language | eng |
| recordid | cdi_pubmed_primary_11221875 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals |
| subjects | Antineoplastic agents Biological and medical sciences CD4-Positive T-Lymphocytes - drug effects CD4-Positive T-Lymphocytes - immunology CD4-Positive T-Lymphocytes - metabolism CD8-Positive T-Lymphocytes - drug effects CD8-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - metabolism Cell Division - drug effects Cytotoxicity, Immunologic - drug effects Drug Synergism Humans Immunotherapy Interferon-gamma - biosynthesis Interleukin-18 - pharmacology Interleukin-2 - pharmacology Killer Cells, Natural - drug effects Killer Cells, Natural - immunology Killer Cells, Natural - metabolism Leukocytes, Mononuclear - drug effects Leukocytes, Mononuclear - immunology Leukocytes, Mononuclear - metabolism Lymphocyte Activation - drug effects Lymphocytes - drug effects Lymphocytes - immunology Lymphocytes - metabolism Lymphoma, B-Cell - immunology Medical sciences Pharmacology. Drug treatments Receptors, Interleukin-2 - biosynthesis Tumor Cells, Cultured Up-Regulation - drug effects |
| title | Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-γ production, and expansion of natural killer cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T14%3A50%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin-18%20(IL-18)%20synergizes%20with%20IL-2%20to%20enhance%20cytotoxicity,%20interferon-%CE%B3%20production,%20and%20expansion%20of%20natural%20killer%20cells&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=SON,%20Young-Ik&rft.date=2001-02-01&rft.volume=61&rft.issue=3&rft.spage=884&rft.epage=888&rft.pages=884-888&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E11221875%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11221875&rfr_iscdi=true |